This is a working overview of subcutaneous dosing, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
On 21 December 2020 the Russian Direct Investment Fund (RDIF), the Gamaleya National Center, AstraZeneca and R-Pharm signed an agreement aimed at the development and implementation of a clinical research program to assess the immunogenicity and safety of the combined use of one of the components of the Sputnik V vaccine developed by the Gamaleya Center, and one of the components of the Oxford–AstraZeneca vaccine. The study program will last 6 months in several countries, and it is planned to involve 100 volunteers in each study program. On 9 February 2021, the Ministry of Health of the Republic of Azerbaijan allowed clinical studies in the country for the combined use of the Oxford–AstraZeneca vaccine and Sputnik Light, stating that the trials would begin before the end of February 2021. On 20 February 2021, in the official Sputnik V Twitter account it was stated that clinical trials have already started.
==== Re-sentencing of death row inmates ==== The amendments of the law also offered a chance for all current death row inmates to have their cases to be reviewed for re-sentencing. Some death row inmates declined to be re-sentenced, including Tang Hai Liang and Foong Chee Peng. The below cases are known cases where death row inmates applied for re-sentencing.
=== American Public Health Association === Inhorn was also involved in the American Public Health Association, the largest organization of public health professionals in the United States. One of the APHA's roles involved developing methodological publications for environmental laboratories, such as Standard Methods for the Examination of Water and Wastewater. Through its Committee on Laboratory Standards and Practices, the APHA developed clinical laboratory books, such as Diagnostic Procedures for Bacterial, Mycotic, and Rickettsial Diseases. In 1971, CLASP determined that a comprehensive book on quality assurance would be useful for laboratory personnel faced with new CLIA guidelines. A task force was established with Inhorn serving as chair, and a meeting was held at CDC in March 1974 to determine the outline of a book consisting of 5 general chapters on QA and 15 chapters on specific health sciences. The book, called Quality Assurance Practices for Health Laboratories, was published in 1978, with Inhorn serving as editor. Inhorn continued to work as the medical director of the WSLH until he retired from UW in 1998 as professor of Pathology and Laboratory Medicine and Preventive Medicine. During the last 20 years of his career and the 10 years after he retired, Inhorn continued to do research and development work in the field of QA. During these decades, major changes were being implemented in the public health laboratory world. For example, it was recognized that QA was necessary in specimen handling and data reporting, as well as in laboratory performance.
Sources: en.wikipedia.org
(1.2) Keey et al. (2000) use a different definition of the fibre saturation point (equilibrium moisture content of wood in an environment of 99% relative humidity). Many properties of wood show considerable change as the wood is dried below the fibre saturation point, including:
Substitution in position 4 of the benzyl affects analgesic potency in the following order: ethoxy > isopropyloxy > n-propyloxy > methoxy > methylthio > H/Cl/F > hydroxy. The most potent of the known compounds contain a nitro group in position 5. The replacement of benzimidazole with an indole has been known from studies conducted by Ciba AG since 1963.
=== Diseases === Verticillium wilt is a major constraint in peppermint cultivation. 'Todd's Mitcham', 'Refined Murray', 'Roberts Mitcham' (see above), and a few other cultivars have some degree of resistance.
==== Capillary electrophoresis ==== Capillary electrophoresis (CE)is emerging as the preferred analytical method for YTX analysis, as it has significant advantages over the other analytical techniques used, including high efficiency, a fast and simple separation procedure, a small sample volume required, and minimal reagent is required. The techniques used for YTX analysis include: CE with ultraviolet (UV) detection and CE coupled to mass spectrometry (MS). CEUV is a good method for YTX analysis, as its selectivity can easily differentiate between YTXs and DSP toxins. The sensitivity of these techniques can, however, be poor due to the low molar absorptivity of the analytes. The technique gives a limit of detection (LOD) of 0.3 μg/ml and a limit of quantification (LOQ)of 0.9 μg/ml. The sensitivity of conventional CEUV can be improved by using micellar electrokinetic chromatography (MEKC). CEMS has the added advantage over CEUV of being able to give molecular weight and/or structural information about the analyte. This enables the user to carry out unequivocal confirmations of the analytes present in the sample. The LOD and the LOQ have been calculated as 0.02 μg/ml and 0.08 μg/ml, respectively, again meeting the European Commission directive.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.